LRRC56 Activators
LRRC56 function through various biochemical pathways to modulate the activity of this protein. Forskolin, a direct activator of adenylyl cyclase, leads to an increase in cellular cAMP levels, which in turn activates protein kinase A (PKA). PKA can phosphorylate LRRC56, resulting in its activation. Similarly, IBMX, by inhibiting phosphodiesterases, prevents the degradation of cAMP, indirectly contributing to the activation of PKA and subsequent phosphorylation of LRRC56. PGE2 operates via its G-protein-coupled receptors to activate adenylate cyclase, again increasing cAMP and activating PKA, which can then target LRRC56.
Bt2cAMP and Sp-cAMPS, both analogs of cAMP, penetrate cells and resist degradation, sustaining PKA activation and thus fostering an environment for LRRC56 activation. Rolipram, Anagrelide, Cilostamide, Etazolate, and Milrinone, all phosphodiesterase inhibitors, raise cAMP levels, with each targeting different phosphodiesterase subtypes, leading to amplified PKA activity. PKA, once activated, can phosphorylate LRRC56. Vinpocetine, on the other hand, inhibits PDE1 to increase both cAMP and cGMP, which could indirectly lead to PKA activation and subsequent phosphorylation of LRRC56. Additionally, Sildenafil, with its primary action on PDE5, influences cGMP levels and, through complex cyclic nucleotide regulatory mechanisms, can also influence cAMP pathways, leading to PKA activation and potential phosphorylation of LRRC56. Each chemical, through its unique interaction with the cell's biochemical pathways, contributes to the state of LRRC56 activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-specific inhibitor of phosphodiesterases, enzymes that degrade cAMP. By preventing the breakdown of cAMP, IBMX indirectly raises intracellular cAMP levels, which could lead to the activation of PKA. As with Forskolin, PKA can phosphorylate and thus activate LRRC56. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G-protein-coupled receptors (GPCRs) leading to the activation of adenylate cyclase and subsequent increase in cAMP levels. This rise in cAMP can activate PKA, which may result in the phosphorylation and activation of LRRC56, promoting its functional role in the cell. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
N6,2'-O-Dibutyryladenosine 3',5'-cyclic monophosphate (Bt2cAMP) is a cell-permeable cAMP analog that activates PKA. Through PKA activation, Bt2cAMP could promote the phosphorylation and activation of LRRC56, enhancing its function within cellular pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which degrades cAMP. Inhibition of PDE4 by Rolipram results in increased cAMP levels, which could lead to the activation of PKA. PKA can then phosphorylate and activate LRRC56 within its functional context. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
it increases cAMP levels within the cell. The resultant activation of PKA can lead to the phosphorylation and activation of LRRC56. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine inhibits PDE1, which leads to increased cAMP and cGMP levels. This increase in cyclic nucleotides can stimulate PKA, potentially leading to the phosphorylation and activation of LRRC56. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of PDE3. By inhibiting PDE3, cilostamide increases cAMP levels, which in turn can activate PKA. This activation of PKA could lead to phosphorylation and activation of LRRC56. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is another PDE3 inhibitor that increases intracellular cAMP levels, leading to PKA activation. PKA can phosphorylate various proteins, which could include LRRC56, thereby activating it. | ||||||